Lung Cancer: 854 Real Stories

854 stories match lung cancer. 428 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage 4 lung cancer with brainstem metastasis: complete remission on chemotherapy

Patient Info: Anonymized, Male, 50s | Stage IV

Metastatic Site: pons, right parietal lobe, brain

Stage IV NSCLC with pontine and right parietal brain metastases achieved complete remission after 2 years of chemotherapy with an anti-VEGF drug; the pontine lesion remained stable, and severe SRS-related central neuropathic pain improved after methadone escalation.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR exon 19 deletion lung cancer: gefitinib after osimertinib toxicity

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion

As of August 2024, Stage IVB EGFR exon 19 deletion lung adenocarcinoma was being treated with gefitinib after osimertinib-induced grade 3 interstitial lung disease; ILD had not recurred, and low-dose prednisolone continued.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage 4 EGFR-mutant lung cancer controlled on gefitinib after osimertinib intolerance

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: EGFR exon 21 L858R mutation

As of August 2024, Stage IVB EGFR L858R lung adenocarcinoma was being treated with gefitinib after grade 3 osimertinib-induced interstitial lung disease; the cancer had not progressed when steroids were completed and ILD had not recurred on gefitinib.

PubMed Central
OutcomeCare Ongoing
Payton, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage III Lung Adenocarcinoma: Payton's Survivor Story

Patient Info: Payton Gibbs, Female, Under 40 | Stage III

As of August 2024, Payton described herself as cancer-free after lobectomy and 4 rounds of adjuvant chemotherapy.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage 4 lung cancer: complete resection after splenectomy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: TTF-1-positive; Synaptophysin-positive; CD56-positive

Metastatic Site: spleen

No evidence of recurrence 1 year after open splenectomy/partial diaphragm resection and later R0 resection of the primary lung tumor for Stage IVB lung cancer with splenic metastasis; systemic therapy was refused.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

EGFR-mutant lung adenocarcinoma transforming to small cell lung cancer during targeted therapy

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion, TP53 mutation, TMB 11 mut/Mb

Metastatic Site: cervical lymph nodes

At the last follow-up in February 2024, 32 months after diagnosis, she was alive and both the primary lung lesion and cervical lymph-node metastasis had decreased on combined chemotherapy, immunotherapy and targeted therapy.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Primary Lung Cancer That Spread to Both Breasts and the Adrenal Gland

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: PD-L1 negative; EGFR, ALK, ROS1, RET, MET exon 14, NTRK and BRAF wild type

Metastatic Site: both breasts, subcutaneous tissue, adrenal gland

After the lung origin was established, she was in good general condition and asymptomatic while first-line systemic therapy was being planned.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage 4 small cell lung cancer: response to carboplatin, etoposide, and atezolizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: CD56-positive; synaptophysin-positive

Metastatic Site: right hilar/mediastinal disease, left adrenal gland,…

Extensive-stage small-cell lung cancer presenting with chronic intestinal pseudo-obstruction improved after 3 cycles of carboplatin, etoposide, and atezolizumab, with PET response and symptomatic improvement; longer-term durability was not reported.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage 4 lung cancer: immunotherapy plus particle therapy halts progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 90%; high tumor mutational burden; PIK3CA ; TP53 mutation; MET mutation

Metastatic Site: left proximal femur

Stage IV oligometastatic NSCLC had good CT response to carboplatin, pemetrexed, and pembrolizumab, then no disease progression 6 months after PULSAR radiotherapy plus pembrolizumab; grade 2 pneumonitis improved with prednisone.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Seven-year response journey in EGFR-mutated metastatic lung adenocarcinoma

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: pleura, brain

About 7 years after presentation with metastatic lung adenocarcinoma, he remained on targeted therapy. Gefitinib controlled the disease for 5 years; after brain progression, osimertinib followed by stereotactic radiation produced a complete intracranial response.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage I Lung CancerLung Cancer

Stage 1 lung adenocarcinoma: NED after surgery alone

Patient Info: Anonymized, Male, 70+ | Stage I

Biomarkers: MET exon 14 skipping; PIK3CA p.; KRAS exon 2 p./D

Both independent early-stage lung adenocarcinomas were resected without lymph-node metastasis; follow-up showed normalized oncologic markers, negative lung-cancer autoantibodies, improved HRCT findings, and no recurrence for 1 year.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Stage 1 EGFR lung adenocarcinoma treated with radiotherapy

Patient Info: Anonymized, Male, 70+ | Stage I

Biomarkers: EGFR exon 19 deletion; other common drivers not detected.

Stage IB EGFR exon 19 deletion lung adenocarcinoma was treated with definitive radiotherapy because of fragile condition after spinal cord infarction; at 5 months, the lesion showed no significant change and there was no recurrence or radiation pneumonitis.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Lung squamous cell carcinoma spreading to bone and intestine

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1 positive in almost all tumor cells

Metastatic Site: bone (left femur), intestine, abdomen

Despite chemotherapy, immunotherapy and radiation, the lung cancer progressed with intestinal and extensive abdominal metastases, cachexia and gastrointestinal bleeding. Palliative care was planned, but he chose discharge and received no further treatment.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA ALK-positive lung adenocarcinoma: pathologic complete response to lorlatinib

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: EML4-ALK fusion; ALK-positive; Napsin A-positive; cytokeratin-positive; TTF-1-positive

He remained disease-free 10 months after surgery while continuing planned adjuvant lorlatinib after neoadjuvant lorlatinib produced partial radiographic response and pathologic complete response.

PubMed Central
OutcomeCancer-Free / NED
Att, who was diagnosed with Stage II Lung CancerLung Cancer

Stage II Lung Cancer: Att's Patient Story

Patient Info: Att Callahan, Female, 70+ | Stage II

As of July 2024, Att was receiving monthly post-surgery immunotherapy and scans every other month after clinical-trial chemoimmunotherapy and lobectomy, with doctors believing they had removed all visible cancer.

MD Anderson
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV PD-L1-negative lung adenocarcinoma: complete response with nivolumab and ipilimumab

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: PD-L1-negative; no targetable molecular alterations on DNA/RNA next-generation sequencing; TP53 alteration reported at 66%

Metastatic Site: left pleural effusion; right adrenal gland;…

As of February 2024, she remained on maintenance nivolumab and ipilimumab after 14 cycles, without significant toxicity and with persistent complete response of Stage IV PD-L1-negative lung adenocarcinoma.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Stage IIIA EGFR-mutated lung adenocarcinoma: surgery after osimertinib

Patient Info: Anonymized, Male, 60s

Biomarkers: EGFR E746_A750 deletion; PD-L1 TPS 15%; TMB 5.01 Muts/Mb; TTF-1 3+; CK7 3+; Ki67 60%

As of July 2024, surveillance CT scans at 2, 6, and 12 months after surgery showed no recurrent malignancy while he continued adjuvant osimertinib.

PubMed Central
OutcomeCancer-Free / NED